About Redx Pharma (LON:REDX)
Redx Pharma Plc, formerly Redx Pharma Ltd, is engaged in drug discovery, pre-clinical development and licensing. The Company is engaged in drug discovery across cancer, infection and autoimmune diseases. The Company has over two programs in its oncology research activity, Smoothened Hedgehog (SMO) and Bruton's Tyrosine Kinase (BTK), which has reached candidate nomination stage. The Company's oncology research activity also include Porcupine program, Colony Stimulating Factor-1 receptor (CSF-1) program, Indoleamine-pyrrole 2,3-dioxygenase (IDO) inhibitor and Pan-Raf inhibitor. The Company's anti-infective candidate compound is an antibiotic that the Company has developed to treat a range of Gram-positive bacterial infections, including resistant strains, such as Methicillin-Resistant Staphylococcus Aureus (MRSA). Its product candidate, RDX003, is a class of antibiotic acting through the type II bacterial topoisomerases. It is also evaluating BTK inhibitor for immunological disorders.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
SectorBio Therapeutic Drugs
Trailing P/E Ratio-1125
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Trailing EPSGBX (0.01)
Return on Equity294.97%
Return on Assets123.97%
Redx Pharma (LON:REDX) Frequently Asked Questions
What is Redx Pharma's stock symbol?
Redx Pharma trades on the London Stock Exchange (LON) under the ticker symbol "REDX."
Who are some of Redx Pharma's key competitors?
Some companies that are related to Redx Pharma include Avacta Group (AVCT), Shield Therapeutics (STX), ValiRx (VAL), Midatech Pharma (MTPH), Evgen Pharma (EVG), Proteome Sciences (PRM), Ariad Pharmaceuticals (ARIA), Cynapsus Therapeutics (CYNA), Dyax (DYAX), Kythera Biopharmaceuticals (KYTH), Ocata Therapeutics (OCAT), Receptos (RCPT), Relypsa (RLYP), Tobira Therapeutics (TBRA) and ZS Pharma (ZSPH).
Who are Redx Pharma's key executives?
Redx Pharma's management team includes the folowing people:
- Neil David Murray, Chief Executive Officer, Co-Founder, Executive Director
- Peter Jackson, Co-Founder, Non-Executive Director
- Derek Lindsay, Chief Operating Officer
- Simon William Thorn, Company Secretary
- Iain Ross, Non-Executive Chairman of the Board
- Bernhard Jurgen Kirschbaum, Non-Executive Director (Age 57)
- Peter McPartland, Non-Executive Director
- Norman James Molyneux, Non-Executive Director
Has Redx Pharma been receiving favorable news coverage?
News headlines about REDX stock have been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Redx Pharma earned a news impact score of 0.20 on Accern's scale. They also gave news coverage about the company an impact score of 44.52 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Redx Pharma?
Shares of REDX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Redx Pharma's stock price today?
One share of REDX stock can currently be purchased for approximately GBX 11.25.
How big of a company is Redx Pharma?
Redx Pharma has a market capitalization of £14.09 million.
How can I contact Redx Pharma?
Redx Pharma's mailing address is Block 33, Mereside,, Alderley Park, MACCLESFIELD, SK10 4TG, United Kingdom. The company can be reached via phone at +44-151-7064747.
MarketBeat Community Rating for Redx Pharma (REDX)MarketBeat's community ratings are surveys of what our community members think about Redx Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Redx Pharma (LON:REDX) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for Redx Pharma (LON:REDX)
No earnings announcements for this company have been tracked by MarketBeat.com
Redx Pharma (LON:REDX) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Redx Pharma (LON:REDX)
No dividend announcements for this company have been tracked by MarketBeat.com
Redx Pharma (LON REDX) Insider Trading and Institutional Ownership History
Redx Pharma (LON REDX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|12/22/2017||Iain Ross||Insider||Buy||102,000||GBX 21||£21,420|
|11/14/2017||Iain Ross||Insider||Buy||348,000||GBX 18||£62,640|
Redx Pharma (LON REDX) News Headlines
Redx Pharma (LON:REDX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Redx Pharma (LON REDX) Stock Chart for Wednesday, March, 21, 2018